[1]滕悦魏艳陈英耀严俊涛刘柳李福明.中药注射剂抗肿瘤治疗的医患偏好及共同决策比较分析[J].中国卫生质量管理,2023,30(02):060-64.[doi:10.13912/j.cnki.chqm.2023.30.2.14 ]
　TENG Yue,WEI Yan,CHEN Yingyao.Comparative Analysis of Physicians' and Patients' Preference and Shared Decision Making of TCM Injection in Anti-tumor Therapy[J].Chinese Health Quality Management,2023,30(02):060-64.[doi:10.13912/j.cnki.chqm.2023.30.2.14 ]
点击复制

中药注射剂抗肿瘤治疗的医患偏好及共同决策比较分析
分享到：

《中国卫生质量管理》[ISSN:1006-7515/CN:CN 61-1283/R]

卷:
第30卷
期数:
2023年02期
页码:
060-64
栏目:
服务质量
出版日期:
2023-02-15

文章信息/Info

Title:
Comparative Analysis of Physicians' and Patients' Preference and Shared Decision Making of TCM Injection in Anti-tumor Therapy
作者:
滕悦魏艳陈英耀严俊涛刘柳李福明
国家卫生健康委员会卫生技术评估重点实验室/复旦大学公共卫生学院
Author(s):
TENG Yue; WEI Yan; CHEN Yingyao
National Health Commission,Key Laboratory of Health Technology Assessment/School of Public Health, Fudan University
关键词:
中药注射剂; 抗肿瘤治疗; 医患偏好; 医患共同决策; 服务质量
Keywords:
TCM Injection; Anti-tumor Therapy; Patients' and Physicians' Preferences; Shared Decision Making; Service Quality
分类号:
R197；R979.1；R944.1；R28
DOI:
10.13912/j.cnki.chqm.2023.30.2.14
文献标志码:
A
摘要:
目的对中药注射剂抗肿瘤治疗的医患偏好及共同决策现状进行比较分析，为相关研究和临床实践提供参考。方法于2020年10月—12月对上海市9家三级医院的肿瘤治疗相关科室的185名医生及347名住院肺癌患者开展问卷调查，通过离散选择实验调查医患对中药注射剂抗肿瘤治疗方案的偏好属性，并采用条件Logit模型及混合Logit模型对医患的偏好属性进行分析，采用医患共同决策测量工具对决策行为进行现状描述与比较分析。结果医生更加关注恶心呕吐及其他毒副反应，患者更加关注疾病控制率及自付治疗费用。而在偏好差异的基础上，78.4%的医生以及90.2%的患者认为其参与的临床决策模式为共同决策模式。结论医患之间的偏好属性及决策模式存在差异，并会在一定程度上影响患者满意度及和谐医患关系。建议激发医生医疗服务积极性，促进医患共同决策。
Abstract:
ObjectiveTo comparatively analyze patients' and physicians' preferences and shared decision making for Traditional Chinese Medicine (TCM) injection treatment of anti-tumor so as to provide references for related research and clinical practice.MethodsFrom October to December 2020, a questionnaire survey was conducted among 185 doctors and 347 inpatients with lung cancer from tumor therapy-related departments of 9 tertiary hospitals in Shanghai. Discrete Choice Experiment (DCE) was conducted to investigate the preference attributes of doctors and patients for TCM injection in anti-tumor therapy. The conditional Logit model and mixed Logit model were used to analyze the preference attributes of doctors and patients, and the doctor-patient shared decision making assessment instrument was used to describe and compare the status quo of decision-making behavior. ResultsDoctors were more concerned about nausea, vomiting and other toxic side effects, and patients were more concerned about disease control rate and out-of-pocket cost for treatment. On the basis of preference differences, 78.4% of doctors and 90.2% of patients believed that the clinical decision-making mode they participated in was shared decision making mode.Conclusion Differences exist in attribute preference and decision-making mode between doctors and patients, which would affect patient satisfaction and harmonious doctor-patient relationship to a certain extent. It is suggested to stimulate the enthusiasm of doctors in medical services and promote shared decision making between doctors and patients.

参考文献/References:

［1］赖桂花,王 菲,周 芳,等.差异视角下中西医治疗肿瘤的协同优势［J］.中医药临床杂志,2022,34(4):599-603. ［2］董子洵,冯佳佳,常佳慧,等.中药注射剂在肿瘤领域的应用研究［J］.中国研究型医院,2019,6(5):14-22. ［3］荣红国,董 玥,于蔚洁,等.政策工具视角下我国中药注射剂发展政策研究［J］.中国药房,2022,33(8):917-922. ［4］陈诗琪,郑 蕊,李幼平,等.中药注射剂临床应用存在问题及说明书的相关思考与建议［J］.世界科学技术-中医药现代化,2018,20(10):1718-1722. ［5］杜治政.共同决策:弥合分歧,营建医患同心的医疗［J］.医学与哲学(A),2018,39(4):1-6. ［6］CARMAN KL, DARDESS P, MAURER M, et al. Patient and family engagement: a framework for understanding the elements and developing interventions and policies［J］. Health Aff (Millwood),2013,32(2):223-231. ［7］COULTER A, ELLINS J. Effectiveness of strategies for informing, educating, and involving patients［J］. BMJ,2007,335(7609):24-27. ［8］CHARMEL PA, FRAMPTON SB. Building the business case for patient-centered care［J］. Healthc Financ Manage,2008,62(3):80-85. ［9］明 坚,魏 艳,孙 辉,等.医患共同决策影响因素及对患者结果的影响［J］.中国卫生质量管理,2017,24(6):90-93.［10］赵 悦,张培海,沈际勇.医患共享决策模式构建［J］.中国卫生质量管理,2022,29(6):55-57，70. ［11］LANCSAR E, LOUVIERE J. Conducting discrete choice experiments to inform healthcare decision making: a user's guide［J］. Pharmacoeconomics,2008,26(8):661-677. ［12］PEARMAIN D, SWANSON J, KROES E, et al. Stated preference techniques:a guide to practice［M］.2nd ed. London:Steer Davies Gleave and Hague Consulting Group Press, 1991：26. ［13］杨 鸣. 中药注射剂干预恶性肿瘤循证评价及与化疗药相互作用的评价方法［D］.北京：北京中医药大学,2021. ［14］孙长河. 中药注射剂联合含铂双药治疗晚期非小细胞肺癌的队列研究［D］.北京：北京中医药大学,2021. ［15］缪碧芳,阮洪光,曾林淼,等.中药注射剂联合放疗治疗非小细胞肺癌的网状Meta分析［J］.中国老年学杂志,2019,39(19):4700-4708. ［16］洪晓华,王光耀,刘体勤,等.八种中药注射剂联合紫杉醇和顺铂化疗方案治疗非小细胞肺癌的网状Meta分析［J］.中国全科医学,2020,23(26):3311-3323. ［17］KRISTON L, SCHOLL I, HLZEL L, et al. The 9-item Shared Decision Making Questionnaire (SDM-Q-9). Development and psychometric properties in a primary care sample［J］. Patient Educ Couns,2010,80(1):94-99. ［18］SCHOLL I, KRISTON L, DIRMAIER J, et al. Development and psychometric properties of the Shared Decision Making Questionnaire:physician version (SDM-Q-Doc) ［J］. Patient Educ Couns,2012,88(2):284-290. ［19］DEGNER LF, SLOAN JA, VENKATESH P. The control preferences scale［J］. Can J Nurs Res,1997,29(3):21-43. ［20］明 坚,魏 艳,柯 雄,等.药物涂层支架技术临床应用中的患者参与决策研究［J］.中国卫生政策研究,2018,11(7):73-77. ［21］明 坚,魏 艳,许 艳,等.医学新技术临床应用患者参与决策及其影响因素分析［J］.中国医院管理,2018,38(3):15-18. ［22］魏 艳.医学新技术转化应用模型构建及实证研究［D］.上海：复旦大学,2017. ［23］HAUBER B, PENROD JR, GEBBEN D, et al. The value of hope: patients' and physicians' preferences for survival in advanced non-small cell lung cancer［J］. Patient Prefer Adherence,2020,14:2093-2104. ［24］袁目北,陈在余.医生诱导需求对我国医疗费用增长的影响［J］.中国药物经济学,2020,15(5):30-37，53. ［25］STIGGELBOUT AM, PIETERSE AH, DE HAES JC. Shared decision making: concepts, evidence, and practice［J］. Patient Educ Couns,2015,98(10):1172-1179.

更新日期/Last Update: 2023-02-15